Evaluation of BNP7787 for the Prevention of Neurotoxicity in Metastatic Breast Cancer Patients Receiving Weekly Paclitaxel
BNP7787 vs. Placebo for Prevention of Paclitaxel Neurotoxicity: A Double-Blind Multicenter Randomized Phase 3 Trial in Patients With Metastatic Breast Cancer
Sponsor: BioNumerik Pharmaceuticals, Inc.
This PHASE3 trial investigates Breast Diseases and Breast Neoplasms and is currently completed. BioNumerik Pharmaceuticals, Inc. leads this study, which shows 10 recorded versions since 2001 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Sep 2022 — Jul 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Sep 2022 [monthly]
Completed PHASE3
-
Apr 2020 — Jan 2021 [monthly]
Completed PHASE3
▶ Show 5 earlier versions
-
Aug 2019 — Apr 2020 [monthly]
Completed PHASE3
-
Nov 2018 — Aug 2019 [monthly]
Completed PHASE3
-
Jun 2018 — Nov 2018 [monthly]
Completed PHASE3
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE3
First recorded
Sep 2001
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- BioNumerik Pharmaceuticals, Inc.
- Lantern Pharma Inc. became Sponsor of Tavocept (BNP7787) IND 051014 as of March 26, 2019.
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
No location information available.